IN SILICO ADMET SCREENING AND MOLECULAR DOCKING OF PHYTOCOMPOUNDS ASSOCIATED WITH Cannabis sativa L. WITH PREDICTED ANTITUBERCULAR POTENTIAL

Authors

DOI:

https://doi.org/10.66104/dq7xz711

Keywords:

Cannabis sativa, tuberculosis, ADMET, molecular docking, InhA, alanine racemase

Abstract

Tuberculosis remains a major public health concern, further aggravated by the emergence of strains resistant to available treatments. In this context, computational tools can support the initial screening of molecules with potential interactions with essential targets of Mycobacterium tuberculosis. This study evaluated phytocompounds associated with Cannabis sativa L. through in silico ADMET prediction and molecular docking against the enzymes InhA and alanine racemase. Initially, 157 phytocompounds were assessed using 49 parameters, including eight physicochemical descriptors calculated with RDKit and 41 pharmacokinetic and toxicological endpoints predicted by Chemprop-RDKit models. Following a multicriteria analysis, 48 compounds were prioritized for subsequent stages. The PDB structures 6SQ9 and 6SCZ were used to represent InhA and alanine racemase, respectively, while the NAD⁺ and PLP cofactors were preserved as structural references for the catalytic sites. The docking protocol for InhA was validated by redocking, yielding an RMSD of 1.825 Å. Cannabisin E showed the most favorable predicted binding energy for InhA, at -10.3 kcal.mol-1, followed by Cannabisin C – Lignanamide, at -9.3 kcal.mol-1. For alanine racemase, Rutin – Flavonoids showed the most favorable result, at -9.3 kcal.mol-1, whereas Cannabisin C – Lignanamide reached -9.0 kcal.mol-1. The predicted complexes involved hydrogen bonds, van der Waals contacts, hydrophobic interactions, and aromatic interactions. Despite the favorable docking results, limitations related to permeability, bioavailability, polarity, molecular weight, and potential toxicological alerts were identified. The evaluated compounds therefore showed predicted in silico antituberculosis potential, although chemical optimization and experimental validation are still required.
Views: 768Downloads: 192

Downloads

Download data is not yet available.

References

AGUIAR, A. S. N.; VELOSO, C. M.; TEJOTA, Y. B. R.; MARTINS, J. L. R.; FAJEMIROYE, J. O.; BORGES, L. L.; CAMARGO, A. J.; DIAS, L. D.; NAPOLITANO, H. B. A comprehensive molecular analysis of cannabidiol: from solid state to antioxidant potential. Computational and Theoretical Chemistry, v. 1241, p. 114890, 2024. DOI: 10.1016/j.comptc.2024.114890. DOI: https://doi.org/10.1016/j.comptc.2024.114890

ANTHONY, K. G. et al. New classes of alanine racemase inhibitors identified by high-throughput screening show antimicrobial activity against Mycobacterium tuberculosis. PLoS ONE, v. 6, n. 5, e20374, 2011. DOI: 10.1371/journal.pone.0020374. DOI: https://doi.org/10.1371/journal.pone.0020374

BERMAN, H. M.; WESTBROOK, J.; FENG, Z.; GILLILAND, G.; BHAT, T. N.; WEISSIG, H.; SHINDYALOV, I. N.; BOURNE, P. E. The Protein Data Bank. Nucleic Acids Research, v. 28, n. 1, p. 235–242, 2000. DOI: 10.1093/nar/28.1.235. DOI: https://doi.org/10.1093/nar/28.1.235

BLASKOVICH, M. A. T. et al. The antimicrobial potential of cannabidiol. Scientific Reports, v. 11, n. 1, p. 1–18, 2021. DOI: 10.1038/s41598-021-81068-4.

BRASIL. Ministério da Saúde. Secretaria de Vigilância em Saúde. Manual de recomendações para o controle da tuberculose no Brasil. 2. ed. Brasília, DF: Ministério da Saúde, 2022.

BRUNING, J. B.; MURILLO, A. C.; CHACÓN, O.; BARLETTA, R. G.; SACCHETTINI, J. C. Structure of the Mycobacterium tuberculosis D-alanine ligase, a target of the antituberculosis drug D-cycloserine. Antimicrobial Agents and Chemotherapy, v. 55, n. 1, p. 291–301, 2011. DOI: 10.1128/AAC.00558-10. DOI: https://doi.org/10.1128/AAC.00558-10

CARABALÍ-ISAJAR, M. L.; RODRÍGUEZ-BEJARANO, O. H.; AMADO, T.; PATARROYO, M. A.; IZQUIERDO, M. A.; LUTZ, J. R.; OCAMPO, M. Clinical manifestations and immune response to tuberculosis. World Journal of Microbiology and Biotechnology, v. 39, n. 8, p. 206, 2023. DOI: 10.1007/s11274-023-03636-x. DOI: https://doi.org/10.1007/s11274-023-03636-x

DARTOIS, V.; DICK, T. Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease. Nature Reviews Drug Discovery, v. 23, p. 381–403, 2024. DOI: 10.1038/s41573-024-00897-5. DOI: https://doi.org/10.1038/s41573-024-00897-5

DHEDA, K. et al. The Lancet Commission on tuberculosis: tuberculosis elimination requires increased investments, accountability, and action. The Lancet, v. 403, n. 10444, p. 2146–2244, 2024. DOI: 10.1016/S0140-6736(24)00650-0. DOI: https://doi.org/10.1016/S0140-6736(24)00650-0

EBERHARDT, J.; SANTOS-MARTINS, D.; TILLACK, A. F.; FORLI, S. AutoDock Vina 1.2.0: new docking methods, expanded force field, and Python bindings. Journal of Chemical Information and Modeling, v. 61, n. 8, p. 3891–3898, 2021. DOI: 10.1021/acs.jcim.1c00203. DOI: https://doi.org/10.1021/acs.jcim.1c00203

HEVENER, K. E.; ZHAO, W.; BALL, D. M.; BABAOGLOU, K.; QI, J.; WHITE, S. W.; LEE, R. E. Validation of molecular docking programs for virtual screening against dihydropteroate synthase. Journal of Chemical Information and Modeling, v. 49, n. 2, p. 444–460, 2009. DOI: 10.1021/ci800293n. DOI: https://doi.org/10.1021/ci800293n

HOHENBERG, P.; KOHN, W. Inhomogeneous electron gas. Physical Review B, v. 136, n. 3B, p. B864–B871, 1964. DOI: 10.1103/PhysRev.136.B864. DOI: https://doi.org/10.1103/PhysRev.136.B864

JUNG, W.; LEE, J.; KIM, H.; LEE, K. Absorption, distribution, metabolism, excretion, and toxicity prediction in drug discovery. Molecules, v. 29, n. 6, p. 1380, 2024. DOI: 10.3390/molecules29061380. DOI: https://doi.org/10.3390/molecules29061380

LAN, Y. et al. Integrating genomic and spatial analyses to describe tuberculosis transmission: a scoping review. The Lancet Microbe, v. 6, n. 8, p. 101094, 2025. DOI: 10.1016/j.lanmic.2025.101094. DOI: https://doi.org/10.1016/j.lanmic.2025.101094

LEE, C.; YANG, W.; PARR, R. G. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. Physical Review B: Condensed Matter, v. 37, n. 2, p. 785–789, 1988. DOI: 10.1103/PhysRevB.37.785. DOI: https://doi.org/10.1103/PhysRevB.37.785

LEE, S.; LEE, Y.; KIM, Y.; KIM, H.; RHYU, H.; YOON, K.; LEE, C.-D.; LEE, S. Beneficial effects of cannabidiol from Cannabis. Applied Biological Chemistry, v. 67, n. 32, 2024. DOI: 10.1186/s13765-024-00867-w. DOI: https://doi.org/10.1186/s13765-024-00867-w

LIPINSKI, C. A.; LOMBARDO, F.; DOMINY, B. W.; FEENEY, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, v. 46, n. 1–3, p. 3–26, 2001. DOI: 10.1016/S0169-409X(00)00129-0. DOI: https://doi.org/10.1016/S0169-409X(96)00423-1

MARRAKCHI, H.; LANEELLE, M. A.; QUÉMARD, A. InhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II. Microbiology, v. 146, n. 2, p. 289–296, 2000. DOI: 10.1099/00221287-146-2-289. DOI: https://doi.org/10.1099/00221287-146-2-289

MORALES, P. et al. Phytocannabinoids and their therapeutic potential in drug discovery. Pharmacological Research, v. 170, p. 105548, 2021. DOI: 10.1016/j.phrs.2021.105548. DOI: https://doi.org/10.1016/j.phrs.2021.105548

OMOTAYO, O. P.; LEMMER, Y.; MASON, S. A narrative review of the therapeutic and remedial prospects of cannabidiol with emphasis on neurological and neuropsychiatric disorders. Journal of Cannabis Research, v. 6, n. 14, 2024. DOI: 10.1186/s42238-024-00222-2. DOI: https://doi.org/10.1186/s42238-024-00222-2

ORGANIZAÇÃO MUNDIAL DA SAÚDE. Global tuberculosis report 2024. Geneva: World Health Organization, 2024.

O’SULLIVAN, S. E. et al. The therapeutic potential of purified cannabidiol. Journal of Cannabis Research, v. 5, n. 1, 2023. DOI: 10.1186/s42238-023-00186-9. DOI: https://doi.org/10.1186/s42238-023-00186-9

PERES, F. F.; LEITE, J. P.; DEL BEL, E. A.; GUIMARÃES, F. S. Cannabidiol as a promising compound for neurological disorders: mechanisms and therapeutic perspectives. Frontiers in Pharmacology, v. 15, 2024. DOI: 10.3389/fphar.2024.1403147. DOI: https://doi.org/10.3389/fphar.2024.1403147

PETTERSEN, E. F.; GODDARD, T. D.; HUANG, C. C.; COUCH, G. S.; GREENBLATT, D. M.; MENG, E. C.; FERRIN, T. E. UCSF Chimera: a visualization system for exploratory research and analysis. Journal of Computational Chemistry, v. 25, n. 13, p. 1605–1612, 2004. DOI: 10.1002/jcc.20084. DOI: https://doi.org/10.1002/jcc.20084

PINZI, L.; RASTELLI, G. Molecular docking: shifting paradigms in drug discovery. International Journal of Molecular Sciences, v. 20, n. 18, p. 4331, 2019. DOI: 10.3390/ijms20184331. DOI: https://doi.org/10.3390/ijms20184331

PO, H. N.; SENOZAN, N. M. The Henderson-Hasselbalch equation: its history and limitations. Journal of Chemical Education, v. 78, n. 11, p. 1499–1503, 2001. DOI: 10.1021/ed078p1499. DOI: https://doi.org/10.1021/ed078p1499

POTLITZ, F.; LINK, A.; SCHULIG, L. Advances in the discovery of new chemotypes through ultra-large library docking. Expert Opinion on Drug Discovery, v. 18, n. 3, p. 303–313, 2023. DOI: 10.1080/17460441.2023.2171984. DOI: https://doi.org/10.1080/17460441.2023.2171984

RAHLWES, K. C.; DIAS, B. R. S.; CAMPOS, P. C.; ALVAREZ-ARGUEDAS, S.; SHILOH, M. U. Pathogenicity and virulence of Mycobacterium tuberculosis. Virulence, v. 14, n. 1, p. 2150449, 2023. DOI: 10.1080/21505594.2022.2150449. DOI: https://doi.org/10.1080/21505594.2022.2150449

SCHRÖDINGER, LLC. The PyMOL Molecular Graphics System, Version 3.1. New York: Schrödinger, LLC, 2025.

SENELLE, G. et al. Towards a better understanding of the long-lasting evolutionary history of Mycobacterium tuberculosis. Tuberculosis, v. 143, p. 102374, 2023. DOI: 10.1016/j.tube.2023.102374. DOI: https://doi.org/10.1016/j.tube.2023.102374

SWANSON, K.; WALTHER, P.; LEITZ, J.; MUKHERJEE, S.; WU, J. C.; SHIVNARAINE, R. V.; ZOU, J. ADMET-AI: a machine learning ADMET platform for evaluation of large-scale chemical libraries. Bioinformatics, v. 40, n. 7, btae416, 2024. DOI: 10.1093/bioinformatics/btae416. DOI: https://doi.org/10.1093/bioinformatics/btae416

WARNER, D. F.; BARCZAK, A. K.; GUTIERREZ, M. G.; MIZRAHI, V. et al. Mycobacterium tuberculosis biology, pathogenicity and interaction with the host. Nature Reviews Microbiology, v. 23, p. 788–804, 2025. DOI: 10.1038/s41579-025-01201-x. DOI: https://doi.org/10.1038/s41579-025-01201-x

WEININGER, D. SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules. Journal of Chemical Information and Computer Sciences, v. 28, n. 1, p. 31–36, 1988. DOI: 10.1021/ci00057a005. DOI: https://doi.org/10.1021/ci00057a005

WRIGHT, N. J. D. A review of the direct targets of the cannabinoids cannabidiol, Δ9-tetrahydrocannabinol, N-arachidonoylethanolamine and 2-arachidonoylglycerol. AIMS Neuroscience, v. 11, n. 2, p. 144–165, 2024. DOI: 10.3934/Neuroscience.2024009. DOI: https://doi.org/10.3934/Neuroscience.2024009

Published

2026-06-27

How to Cite

Pismel, G. M., Sanches, A. de P. A., Filho, W. L. de S., Sousa, A. Q. D. de, Corrêa, L. P., & Carneiro, A. da S. (2026). IN SILICO ADMET SCREENING AND MOLECULAR DOCKING OF PHYTOCOMPOUNDS ASSOCIATED WITH Cannabis sativa L. WITH PREDICTED ANTITUBERCULAR POTENTIAL. REMUNOM, 13(14), 1-33. https://doi.org/10.66104/dq7xz711

Similar Articles

1-10 of 50

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)